Iqymune

Human Normal Immunoglobulin, the active ingredient in Iqymune, is an immunoglobulin presented as a sterile solution for intravenous use. It provides passive immunity by supplying pooled IgG antibodies and is used in patients with antibody deficiencies or secondary immune compromise.

GNH USA supplies Iqymune as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and other healthcare facilities worldwide.

Iqymune is used in immunoglobulin replacement therapy and immune modulation for several clinical conditions.

- Primary immunodeficiency diseases: restores deficient IgG levels to reduce infection frequency. - Secondary immunodeficiency (e.g., post‑transplant or chemotherapy): provides passive antibodies to protect against opportunistic infections. - Immune thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. - Kawasaki disease (acute phase): reduces coronary artery inflammation and fever in children.

Common Side Effects: - Headache: mild to moderate pain often occurring during or after infusion. - Fever and chills: transient rise in body temperature and shivering. - Nausea or vomiting: gastrointestinal discomfort during infusion. - Fatigue: feeling of tiredness post‑infusion. - Infusion‑related reactions: erythema, itching, or mild hypotension. - Muscle aches: soreness in limbs or back.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: clot formation in veins or arteries. - Acute renal failure: sudden loss of kidney function, especially in high‑risk patients. - Aseptic meningitis: inflammation of meninges without infection. - Hemolysis: destruction of red blood cells leading to anemia. - Severe hypotension: dangerous drop in blood pressure during infusion.

Before initiating therapy, clinicians should consider several safety measures.

- Assess IgG levels before initiation: measure baseline serum IgG to determine dosing need. - Monitor renal function: check creatinine in patients with risk factors such as dehydration or nephrotoxic drug use. - Avoid in patients with known IgA deficiency and anti‑IgA antibodies: risk of severe anaphylactic reactions. - Use caution in patients with thrombotic risk: evaluate history of clotting disorders before infusion. - Infusion rate: start low and increase gradually to minimize infusion‑related reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iqymune may interact with several medications and vaccines.

Major Interactions (Avoid): - Live vaccines: concurrent administration can reduce vaccine efficacy and increase infection risk. - Anticoagulants (e.g., warfarin): heightened risk of thrombotic complications. - Nephrotoxic agents (e.g., aminoglycosides, NSAIDs): may exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Corticosteroids: combined immunosuppression may increase infection susceptibility. - Other immunosuppressants (e.g., rituximab): additive effects on immune function require monitoring. - Non‑live vaccines: possible reduced immunogenic response; timing should be coordinated.